Couragen Biopharmaceutics, LLC is a North Carolina startup biotechnology company whose mission is to develop gene therapy and protein therapy products for pre-clinical and clinical use. Couragen uses a technology platform based on adeno-associate virus (AAV) vectors, a safe and powerful vehicle, to deliver therapeutic genes to a variety of cells, tissues and even the whole body for genetic and chronic diseases treatment. In addition, the company also provides custom-designed AAV vectors, which are in high demand as a tool for laboratory research such as molecular biology, genetics and mechanisms of pathogenesis and even engineering of animal models.